Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2221-2240 of 3,900 trials

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinology

Castration-Resistant Prostate Cancer: CC-1 Antibody Study

We are testing a new bispecific antibody for patients with castration-resistant prostate cancer. The study aims to evaluate its safety and how well it may work compared to existing treatments.

Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology

Cirrhosis Due to NASH/MASH: Efruxifermin Study

We are testing a new medication, Efruxifermin, for people with compensated cirrhosis from NASH/MASH. The study aims to see if it improves liver health and reduces related health risks compared to a placebo.

Non-Alcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementEndocrinologyHepatology

Metastatic Renal Cell Carcinoma: Temferon Gene Therapy

We are testing a new gene therapy using modified stem cells for patients with metastatic renal cell carcinoma. The study aims to evaluate the safety and biological response to a single dose of Temferon.

Metastatic Kidney Cancer1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Bladder Cancer: EG-70 Treatment Study

We are testing a new treatment called EG-70 for patients with bladder cancer that hasn't responded to standard therapy. The study aims to see if it can help improve outcomes and quality of life for these patients.

Non-muscle invasive bladder cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Acute Heart Failure: Intra-Abdominal Pressure and Ultrasound Study

We are exploring whether using intra-abdominal pressure and ultrasound can improve diuretic treatment for patients with acute heart failure. This study aims to see if these methods help reduce congestion and improve recovery compared to standard treatment.

Acute Heart Failure>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Episodic Migraine: MEDI0618 Treatment Study

We are investigating whether the new medication MEDI0618 can help reduce the number of migraine days for adults with episodic migraines compared to a placebo. This study aims to assess its safety and effectiveness.

Migraine6-12 monthsEfficacy phase (II)Investigational MedicinesNeurology

Reducing Radiation in PET Scans: BELOW Trial

We are studying how to lower the dose of radiopharmaceuticals used in PET scans. This research aims to ensure effective imaging while minimizing radiation exposure for patients.

Cancer>2 yearsSafety phase (I)OncologyOtolaryngology

Severe Alcohol-Associated Hepatitis: INT-787 Study

We are testing a new medication, INT-787, for individuals with severe alcohol-associated hepatitis. The goal is to see if it can help slow down the progression of this serious liver disease.

Alcoholic Hepatitis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

Relapsing-Remitting Multiple Sclerosis>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

EGL-001 for Advanced Solid Tumors

We are testing a new treatment called EGL-001 in adults with advanced or metastatic solid tumors. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced and Metastatic Solid Tumors1-2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Breast Cancer: PF-07220060 with Letrozole

We are studying a new medicine, PF-07220060, combined with letrozole for adults with HR-positive, HER2-negative advanced breast cancer. This trial compares its effectiveness to standard treatments in patients who haven't had prior systemic therapy.

Advanced/Metastatic Breast CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Breast Cancer: Elacestrant and Everolimus Study

We are studying a combination of elacestrant and everolimus for patients with advanced breast cancer that has specific mutations. The goal is to see if this treatment helps delay cancer progression compared to a placebo.

Advanced Estrogen Receptor-Positive Breast Cancer1-2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyOncology

Recurrent Lower Respiratory Tract Infections: Buccalin Tablets

We are studying Buccalin tablets to see if they can help prevent recurrent lower respiratory tract infections. This trial aims to gather more information on their safety and effectiveness.

Recurrent Lower Respiratory Tract InfectionsMonitoring phase (IV)16-20 visitsStandard MedicinesInternal MedicinePulmonology

Menstrual Migraine: Atogepant Study

We are testing Atogepant to see if it can help prevent menstrual migraines. The study will also look at its safety and how well people tolerate the treatment.

Menstrual Migraine6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGynecology and ObstetricsNeurology

Sepsis Treatment: New Antibiotic Dosing Strategy

We are testing a new way to dose beta-lactam antibiotics for critically ill patients with sepsis. The goal is to see if this improves their recovery in the ICU.

Sepsis1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Lung Cancer: Sacituzumab and Zimberelimab Treatment

We are studying a combination of two medications for patients with non-small cell lung cancer who have had surgery but are not disease-free. The goal is to see if this treatment can help prevent cancer from returning.

Resectable Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPulmonology

Fecal Microbiota Transplantation for Blood Cancer Stem Cell Transplant Patients

We are studying whether fecal microbiota transplantation can help prevent complications after stem cell transplants in patients with blood cancers. This trial will assess its effects on survival and quality of life.

Patients Post Allogeneic Stem Cell Transplant>2 yearsEfficacy phase (II)Investigational MedicinesHematologyOncology

B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

Indolent B-Cell Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Esophageal Adenocarcinoma: The PRESTO Trial

We are studying a combination of durvalumab and chemoradiation to see if it can help preserve the esophagus in patients with early-stage cancer. This trial aims to avoid surgery and assess treatment effectiveness and safety.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology